Get the Stockscreener App
5.135
4.15%
0.195
Niagen Bioscience Inc stock is traded at $5.135, with a volume of 3.37M.
It is up +4.15% in the last 24 hours and up +0.29% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$4.94
Open:
$5.69
24h Volume:
3.37M
Relative Volume:
3.56
Market Cap:
$410.60M
Revenue:
$116.30M
Net Income/Loss:
$17.73M
P/E Ratio:
24.45
EPS:
0.21
Net Cash Flow:
$20.88M
1W Performance:
-0.68%
1M Performance:
+0.29%
6M Performance:
-45.32%
1Y Performance:
+0.00%
1-Day Range:
$4.98
$5.78
1-Week Range:
$4.725
$5.78
52-Week Range:
$4.725
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
5.145 | 394.24M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.07 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.26 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.50 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.25 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.50 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Niagen Bioscience (NAGE) Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook - simplywall.st
Niagen Bioscience Rallies 18% After Hours: Here's Why - Benzinga
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED) - Benzinga
Niagen Bioscience Inc (NAGE) Q4 2025 Earnings Call Highlights: S - GuruFocus
Niagen Bioscience (NAGE) Reports Strong Q4 and Ambitious 2026 Pl - GuruFocus
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income I - PharmiWeb.com
Niagen Bioscience (NAGE) Earnings Transcript - The Globe and Mail
Niagen Bioscience (NAGE) Surges 39% Following Q4 Results and Pos - GuruFocus
Niagen Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: Niagen Bioscience’s Q4 2025 revenue grows 16% - Investing.com Nigeria
Niagen Bioscience (NAGE) Surpasses Q4 Revenue Expectations - GuruFocus
Niagen Bioscience Reports Strong 2025 Results, Strategic Shift - TipRanks
Niagen Bioscience Q4 Earnings Assessment - Benzinga
Niagen Bioscience soars 38% on blowout Q4 results - Investing.com South Africa
Niagen Bioscience: Fourth Quarter Financial Overview - Bitget
Niagen Bioscience: Q4 Earnings Snapshot - KVUE
Niagen Bioscience earnings beat by $0.03, revenue topped estimates - Investing.com
Niagen Bioscience announces financial results for fourth quarter and fiscal 2025, ChromaDex Corp. states - Traders Union
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 - The Joplin Globe
Niagen Bioscience more than doubles 2025 profit as Tru Niagen sales jump - Stock Titan
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 205% Upside in the Biotech Sector - DirectorsTalk Interviews
EPS Watch: Is Niagen Bioscience Inc a cyclical or defensive stockWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Niagen Bioscience sells reference standards unit to LGC By Investing.com - Investing.com Canada
Niagen Bioscience to streamline operations with the sale of Chromadex reference standards business to LGC - marketscreener.com
VHG Labs, Inc. acquired ChromaDex's analytical reference standards and services business from Niagen Bioscience, Inc.. - marketscreener.com
Niagen Bioscience sells reference standards unit to LGC - Investing.com
Niagen Bioscience Divests Non-Core Analytical Standards Business - TipRanks
Niagen Bioscience To Streamline Operations With The Sale Of Chromadex Reference Standards Business To LGC - TradingView
Niagen Bioscience sells ChromaDex reference standards business to LGC in all-cash deal - TradingView
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire
Niagen Bioscience secures patent for IV NAD+ precursor delivery - Investing.com India
Assessing Niagen Bioscience (NAGE) Valuation After Recent Share Price Volatility - simplywall.st
Niagen’s NAD+ Bet Is Paying Off, But The Price Is Steep - Finimize
Niagen Bioscience secures patent for IV NAD+ precursor delivery By Investing.com - Investing.com Australia
ChromaDex Corp. reveals new U.S. patent on intravenous NAD plus precursor methods - Traders Union
Niagen Flat on Patent News - Baystreet.ca
Niagen Bioscience secures new U.S. patent for nicotinamide riboside - marketscreener.com
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen - Business Wire
Aug Wrap: Will Niagen Bioscience Inc outperform its industry peers2025 Market Outlook & Safe Entry Momentum Tips - baoquankhu1.vn
Retail Trends: Can Niagen Bioscience Inc grow without dilutionWeekly Trading Summary & Real-Time Price Movement Reports - baoquankhu1.vn
Niagen Bioscience (NAGE) SVP and General Counsel receives 41,420 stock options - Stock Titan
Niagen Bioscience (NAGE) CFO receives grant of 62,131 employee stock options - Stock Titan
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Hillsdale Investment Management Inc. Buys Shares of 320,272 Niagen Bioscience, Inc. $NAGE - MarketBeat
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 219.84% Potential Upside Awaits Investors - DirectorsTalk Interviews
Q4 Earnings Estimate for NAGE Issued By HC Wainwright - Defense World
Can Niagen Bioscience Inc. deliver consistent EPS growth2025 Growth vs Value & Consistent Profit Trade Alerts - mfd.ru
Can Niagen Bioscience Inc. grow without dilutionQuarterly Trade Summary & Free Reliable Trade Execution Plans - mfd.ru
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Potential Upside of Over 210% Draws Investor Attention - DirectorsTalk Interviews
Is Niagen Bioscience Inc. a cyclical or defensive stockEarnings Beat & Real-Time Buy Signal Alerts - mfd.ru
Niagen Bioscience Inc Stock (NAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):